Alnylam Signs $2 Billion AI Drug Discovery Agreement
TL;DR. Alnylam entered a deal with an unnamed partner, potentially generating $2 billion by 2026 for AI-powered drug discovery. - The AI collaboration focuses on identifying novel targets for RNAi therapeutics to accelerate drug development. - This partnership deepens Alnylam's use of artificial intelligence in its R&D pipeline. - The financial structure includes upfront payments, research funding, and milestone-based rewards for successful discoveries.
- Alnylam secured a potential $2 billion AI drug discovery deal by 2026.
- The agreement centers on using artificial intelligence to find new targets for RNAi therapies.
- The partnership aims to enhance Alnylam's R&D capabilities and accelerate its drug pipeline.